1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Issue 10184 (11th May 2019) Authors: Heerspink, Hiddo J L; Parving, Hans-Henrik; Andress, Dennis L; Bakris, George; Correa-Rotter, Ricardo; Hou, Fan-Fan; Kitzman, Dalane W; Kohan, Donald; Makino, Hirofumi; McMurray, John J V; Melnick, Joel Z; Miller, Michael G; Pergola, Pablo E; Perkovic, Vlado; Tobe, Sheldon; Yi, Tingting; Wigderso... Journal: Lancet Issue: Volume 393:Issue 10184(2019) Page Start: 1937 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Issue 10367 (3rd December 2022) Authors: Schlaich, Markus P; Bellet, Marc; Weber, Michael A; Danaietash, Parisa; Bakris, George L; Flack, John M; Dreier, Roland F; Sassi-Sayadi, Mouna; Haskell, Lloyd P; Narkiewicz, Krzysztof; Wang, Ji-Guang; Reid, Christopher; Schlaich, Markus; Katz, Ivor; Ajani, Andrew; Biswas, Sinjini; Esler, Murray; ... Journal: Lancet Issue: Volume 400:Issue 10367(2022) Page Start: 1927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗